NEI Research News

A College of Veterinary Medicine & Biomedical Sciences and College of Pharmacy team believes the medication may also translate to the treatment of cataracts and uveitis in humans.

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A’s pro-inflammatory activity, according to a new NEI study.

Methotrexate and the more expensive mycophenolate mofetil performed similarly in a head-to-head clinical trial that compared the two drugs for treating noninfectious uveitis, an eye disease that accounts for up to 15% of blindness in the U. S.

A research team at Massachusetts Eye and Ear has shown that microglia, the primary immune cells of the central nervous system—including the retina of the eye—serve as “gatekeepers,” or biosensors and facilitators, of neuroinflammation...

Researchers at the University of North Texas Health Science Center have shown that the MDM2 inhibitor class of drugs can treat uveitis in mice.

Delivery of corticosteroids directly into the eye is more effective than injections adjacent to the eye, according to results from a comparative clinical trial of macular edema in patients with noninfectious uveitis.

NIH scientists have simplified manufacturing and dosing of a potential drug candidate for the autoimmune eye disease uveitis—a vision-threatening condition that accounts for about 15 percent of blindness in the U.S.

Systemic therapy consisting of corticosteroids and immunosuppressants preserved vision of uveitis patients better – and had fewer adverse outcomes – than a long-lasting corticosteroid intraocular implant, according to a clinical trial funded by NEI.

The inflammatory eye disorder autoimmune uveitis occurs when a person’s immune system goes awry, attacking proteins in the eye.

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.